Arca
Skip to content
Tools
Tools

Shiseido Future Solutions LX Triple Points Bonus contains SPF 50+ (octinoxate 4.9%

Recall D-0218-2018, part of FDA recall event 78791. See Shiseido America's company page.

SHISEIDO AMERICA INC. started this Class II drug recall on Dec 14, 2017 (voluntary: firm initiated); FDA lists it as terminated, terminated Jun 24, 2021.

  • Classification: Class II
  • Started: Dec 14, 2017
  • Status: Terminated
  • Products in this event: 5

Why It Was Recalled

Class II

GMP Deviations: manufacturing of API material did not meet GMP and quality requirements.

Record

Product
Shiseido Future Solutions LX Triple Points Bonus contains SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc oxide 15.4%), packaged in 15 mL tubes, Shiseido Americas Corporation Dist. New York, NY 10022, NDC 58411-256-60
Quantity
N/A
Lots and codes
SKU#: 95284
Distribution
Product was distributed nationwide.
Recalling firm
SHISEIDO AMERICA INC., East Windsor, NJ, United States
How the firm notified
Letter
FDA classified
Jan 12, 2018

Other Products in This Recall

Recall event 78791

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.